| STD
Information Center > STD
News > HPV Findings
STD Information Center Menu: |
|
Findings From
Pharmacor HPV Study
(onlinedatingmagazine.com -
December 1, 2003) A study by Decision Resources Pharmacor
finds that the human papillomavirus (HPV) market will
grow from approximately $135 million in 2002 to $1.4
billion in 2012.
From the Study
Human papillomavirus (HPV)
infection, one of the most common sexually transmitted
diseases
(STDs), is now recognized as the causative agent of
both genital warts and cervical dysplasia, the two
major clinical manifestations of HPV. Currently, more
than 1 million people are afflicted with genital warts
and almost 13 million have HPV-related cervical dysplasia
(in the term cervical dysplasia, we include the range
of premalignant states - low-grade and high-grade squamous
cell intraepithelial lesions [SIL] - that precede invasive
cancer).
Current treatments for these diseases
- which include surgery, cryotherapy, and topical agents
(for
genital warts only) - are associated with significant
unmet need. Because surgical intervention is costly
and, in the case of cervical dysplasia, can impact
a woman’s ability to bear children, experts say
that significant opportunity exists for pharmacological
agents that can treat or prevent HPV infection.
Furthermore,
neither surgery nor current pharmacological agents
eradicate the underlying HPV infection, and many
patients suffer from recurrent episodes of disease.
Several
therapeutic and prophylactic vaccines are poised
to fill this need, and these novel classes, particularly
the prophylactic vaccines, will drive the majority
of market growth over our study period. Among the key findings of our research and analysis
are the following:
- The human papillomavirus (HPV) market offers significant
opportunity for development, particularly in treatment
of cervical HPV infection, which is associated with
significant morbidity and cost because of the cancer
that can result from HPV-related cervical dysplasia.
Sales in the HPV market in 2002 were a relatively modest
$135 million; growth in the market is expected with
the introduction of prophylactic vaccines.
- A prophylactic vaccine that prevents HPV infection
is the most pressing need in this indication, especially
one that offers broad coverage against the major HPV
types associated with cervical dysplasia and subsequent
cervical cancer.
- The HPV drugs with the highest sales (and no generics
competition) are the immunomodulators for treatment
of genital warts. (Note that surgery is the only current
treatment option for cervical dysplasia.) During our
study period, however, the emerging prophylactic vaccines
for prevention of genital warts and cervical dysplasia
will drive growth and dominate the market in 2012.
|
